Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose bivalirudin during PCI for acute coronary syndrome
ChiCTR1900024001Phase 4Not yet recruiting
- Sponsor
- Characteristic Medical Center of Chinese People's Armed Police Force
- Start
- Jul 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of bivalirudin and heparin in acute coronary syndrome (ACS) (3 arms), sponsored by Characteristic Medical Center of Chinese People's Armed Police Force. Primary endpoint: Major adverse cardiac events. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
bivalirudinheparin
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on ChiCTR1900024001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024001.